Optimization of Selective and CNS Penetrant Alkyne-Based TREK Inhibitors: The Discovery and Characterization of ONO-9517601 (VU6022856) and ONO-7927846 (VU6024391)

Characterization of Next-Generation Inhibitors for the Inward-Rectifier Potassium Channel K_ir2.1: Discovery of VU6080824

Highly Potent and Subtype-Selective Sperm-Specific Potassium Channel SLO3 Inhibitors Display High Tissue Exposure in the Murine Female Reproductive Tract

Cryo-EM reveals an extrahelical allosteric binding site at the M5 mAChR

Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer’s disease: a single ascending-dose study in healthy participants

Discovery of a Novel sp³-Rich M₁ Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping

Correction to “Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator <i>In Vivo</i> Tool Compound”

Total Synthesis of Kavaratamides A–C and Unnatural Analogs

Discovery of Pre-Clinical Candidate <b>VU6008055</b>/<b>AF98943</b>: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M₄ Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy

Discovery of ONO-TR-772 (VU6018042): A Highly Selective and CNS Penetrant TREK Inhibitor <i>in Vivo</i> Tool Compound

Discovery of Thieno[3,2-<i>b</i>]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5

Total Synthesis and Pharmacological Evaluation of Phochrodines A–C

Application of Deuterium in an M₁ Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422

Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator <i>In Vivo</i> Tool Compound